|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
AU2019338207B2
(en)
|
2018-09-10 |
2025-01-02 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
US12208099B2
(en)
|
2018-09-10 |
2025-01-28 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
US12377101B2
(en)
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
WO2021139748A1
(en)
*
|
2020-01-08 |
2021-07-15 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Spirocyclic tetrahydroquinazolines
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CN116034106B
(zh)
|
2020-06-02 |
2025-11-04 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
|
|
US12655160B2
(en)
|
2020-08-04 |
2026-06-16 |
Mirati Therapeutics, Inc. |
KRAS G12D inhibitors
|
|
WO2022040469A1
(en)
*
|
2020-08-19 |
2022-02-24 |
The Trustees Of The Stevens Institute Of Technology |
Spiro compounds as kras inhibitors
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
EP4216951B1
(en)
|
2020-09-22 |
2026-04-01 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
EP4262807A4
(en)
|
2020-12-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Azachinazoline pan-KRAS inhibitors
|
|
WO2022133038A1
(en)
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN114685502A
(zh)
*
|
2020-12-25 |
2022-07-01 |
由理生物医药（上海）有限公司 |
作为kras-g12c抑制剂的螺环类化合物
|
|
CN114805311B
(zh)
*
|
2021-01-21 |
2024-10-29 |
苏州亚盛药业有限公司 |
螺环茚
|
|
US20240219403A1
(en)
*
|
2021-04-09 |
2024-07-04 |
Memorial Sloan-Kettering Cancer Center |
Methods for inhibiting kras oncoprotein through enhanced gtpase activity
|
|
WO2022240971A2
(en)
*
|
2021-05-11 |
2022-11-17 |
1200 Pharma Llc |
Kras g12d inhibitors and uses thereof
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
CA3237274A1
(en)
*
|
2021-11-09 |
2023-05-19 |
1200 Pharma Llc |
Select kras g12c inhibitors and uses thereof
|
|
TW202337432A
(zh)
*
|
2021-12-01 |
2023-10-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
CR20240233A
(es)
|
2021-12-01 |
2024-07-17 |
Univ Vanderbilt |
Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
KR20250109197A
(ko)
|
2022-11-21 |
2025-07-16 |
트리라인 바이오사이언시스, 인크. |
스피로환식 디하이드로피라노피리미딘 KRas 억제제
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
KR20260054710A
(ko)
|
2023-08-17 |
2026-04-22 |
트리라인 바이오사이언시스, 인크. |
스피로시클릭 디히드로피라노피리미딘 KRas 저해제
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
WO2025237091A1
(zh)
*
|
2024-05-17 |
2025-11-20 |
中山优理生物医药有限公司 |
螺环类化合物的制备方法及其中间体
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|